Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29418568 | 1.00 | SIGMAR1 (0.53) | SIGMAR1TSHRHTR2CENPP2SLC6A2 | |
| Hydrochloric Acid SCHEMBL1624880 | 0.99 | SIGMAR1 (0.52) | SIGMAR1TSHRHTR2CENPP2SLC6A2 | |
| SCHEMBL29418490 | 0.96 | SIGMAR1 (0.55) | SIGMAR1TSHRHTR2CENPP2SLC6A2 | |
| SCHEMBL10565202 | 0.92 | SLC6A2 (0.52) | SIGMAR1TSHRHTR2CSLC6A2SLC6A4 | |
| SCHEMBL13738856 | 0.92 | SLC6A2 (0.52) | SIGMAR1TSHRHTR2CSLC6A2SLC6A4 | |
| SCHEMBL7762819 | 0.92 | SLC6A2 (0.52) | SIGMAR1TSHRHTR2CSLC6A2SLC6A4 | |
| SCHEMBL803682 | 0.90 | SIGMAR1 (0.53) | SIGMAR1TSHRHTR2CENPP2SLC6A4 | |
| SCHEMBL1224067 | 0.87 | HTR2C (0.55) | SIGMAR1TSHRHTR2CENPP2SLC6A2 | |
| SCHEMBL20863082 | 0.86 | SLC6A2 (0.50) | SIGMAR1TSHRHTR2CENPP2SLC6A2 | |
| SCHEMBL17707888 | 0.86 | SLC6A2 (0.50) | SIGMAR1TSHRHTR2CENPP2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-15 | — | — | US | disclosed |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3461821-B1 | INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10604504-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190248760-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-15 | — | — | US | disclosed |
| US-10329274-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-25 | — | — | US | disclosed |
| US-20190119245-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3461821-A1 | INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9920031-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-20 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | SIGMAR1 2218/4885TSHR 2356/4885HTR2C 4799/4885 |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | SIGMAR1 882/4885TSHR 4639/4885HTR2C 4855/4885 |
| US-20190248760-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | SIGMAR1 1668/4885TSHR 877/4885HTR2C 1098/4885 |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | SIGMAR1 1668/4885TSHR 877/4885HTR2C 1098/4885 |
| US-10329274-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | SIGMAR1 1668/4885TSHR 877/4885HTR2C 1098/4885 |
| US-20190119245-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | SIGMAR1 1668/4885TSHR 877/4885HTR2C 1098/4885 |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | SIGMAR1 1668/4885TSHR 877/4885HTR2C 1098/4885 |
| US-20200165222-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | SIGMAR1 1668/4885TSHR 877/4885HTR2C 1098/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | SIGMAR1 2218/4885TSHR 2356/4885HTR2C 4799/4885 |
| US-10604504-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | SIGMAR1 1668/4885TSHR 877/4885HTR2C 1098/4885 |
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | SIGMAR1 369/4885TSHR 586/4885HTR2C 549/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | SIGMAR1 2218/4885TSHR 2356/4885HTR2C 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.